Skip to main content
Clinical Trials/NCT06561438
NCT06561438
Completed
Phase 3

Postoperative Pain Management Following Laparoscopic Cholecystectomy- Vortioxetine

Future University in Egypt1 site in 1 country86 target enrollmentAugust 6, 2024

Overview

Phase
Phase 3
Intervention
Vortioxetine 20Mg Tab
Conditions
Postoperative Pain
Sponsor
Future University in Egypt
Enrollment
86
Locations
1
Primary Endpoint
VAS score (Visual analogue scale)
Status
Completed
Last Updated
10 months ago

Overview

Brief Summary

Postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. No. study has investigated Vortioxetine as an adjuvant to standard care for postoperative pain management in patients undergoing LC

Detailed Description

Postoperative pain is a main challenge for delayed hospital discharge in Laparoscopic cholecystectomy. . Postoperative pain management is essential and the inability to treat acute pain appropriately in the first 48 postoperative hours represents a risk factor for developing chronic pain. Vortioxetine (VO) is a multimodal serotonergic antidepressant with a unique mechanism of action that is effective in treating neuropathic pain. The purpose of this study is evaluating the efficacy and tolerability of preoperative oral administration of Vortioxetine on postoperative pain control in patients undergoing LC

Registry
clinicaltrials.gov
Start Date
August 6, 2024
End Date
June 7, 2025
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hoda Mohamed

Principal investigator

Future University in Egypt

Eligibility Criteria

Inclusion Criteria

  • Patients who are scheduled to undergo elective LC.
  • Adults (males and/or females) between the ages of 18-70 years old.

Exclusion Criteria

  • Chronic pain other than cholelithiasis.
  • Patients who received analgesics or sedatives 24 h before scheduled surgery.
  • Severe hepatic (Child Pugh Class B and C) and renal dysfunction (CrCl \<30ml/min)
  • Previous allergic response to vortioxetine.
  • Pregnancy and lactation
  • Patients with communication problems, cognitive dysfunction, or psychological disorders
  • Daily corticosteroid use

Arms & Interventions

Intervention arm

20 mg oral vortioxetine tablet 2 hours before the procedure

Intervention: Vortioxetine 20Mg Tab

Outcomes

Primary Outcomes

VAS score (Visual analogue scale)

Time Frame: 2 hours, 4 hours, 8 hours, 12 hours, 24 hours

Pain intensity: VAS score from 0 to 100 mm In which 0 means no pain, and 100 means the worst pain possible

Secondary Outcomes

  • Time to analgesic request(24 hours)
  • Quality of life (QoL) after laparoscopic cholecystectomy (LC)(3 months)

Study Sites (1)

Loading locations...

Similar Trials